|
Click
on company name or logo to visit the company website.
 Accelrys
(formerly Molecular Simulations Inc.) delivers software and services
based on its industry-leading expertise in informatics and computation
for the biological, chemical, and materials sciences. The result is
the accelerated design, discovery, and development of pharmaceuticals,
chemicals, and materials. Accelrys meets these needs with an unrivalled
portfolio of technology, expertise developed through years of success
in developing and applying scientific software, a worldwide scientific
and sales presence, financial strength, and active partnerships with
major pharmaceutical, biotechnology, and chemical companies. Accelrys
is a subsidiary of Pharmacopeia Inc. |
 Through
the use of a functional proteomics technology platform ACE BioSciences
is building novel Protein Interaction Network (PIN) databases of pathogenic
microorganisms. We will collaborate with the pharmaceutical and biotechnology
industries to use our PIN databases to identify disease markers and
novel drug targets for human diseases caused by pathogenic microorganisms.
|
| ACLARA
BioSciences
ACLARA is a pioneer in the field of microfluidics, or lab-on-a-chip
technology, with access to the wide range of technology and intellectual
property required to broadly address key markets such as genomics
(RNA and DNA analysis), proteomics, multiplexed DNA sample preparation
and pharmaceutical drug screening. To penetrate these large and rapidly
growing markets, we are developing multiple products that incorporate
microfluidics, the controlled movement of small volumes of fluids
through an array of microscopic channels on ACLARA's disposable plastic
LabCard™ chip products. Additionally, ACLARA is developing unique
and proprietary chemistries that will enable key applications. These
technologies are designed to allow researchers to rapidly perform
large numbers of chemical and biological measurements in a miniaturized,
integrated and automated format. |
ActivX Biosciences is pioneering the field of activity-based proteomics
to increase the speed and cost-effectiveness of target discovery and
drug development. The company is developing a high-throughput chemistry
platform for identifying and analyzing active proteins in all ranges
of abundance in any biological sample. Current genomics and proteomics
technologies do not report on protein activity - an end-stage event
that regulates both health and disease. By providing the first global
analysis of protein activities, ActivX's next-generation proteomics
approach addresses the gap between the data generated by standard
genomics and proteomics techniques and the therapeutic relevance of
those data. |
 The
Company's proprietary, integrated drug discovery process is designed
for rapid advancement of small molecule programs from gene to clinic.
Affinium is actively engaged on its own internal small molecule programs.
The Company's processes enable high throughput target production,
determination of target function/structure, and determination of target
structure with bound chemicals to enhance and accelerate chemistry
for new medicines. The Company's Pharmaceutical Proteomics™ processes
are enhanced by strategic partnerships with Bruker Daltronics and
Bruker BioSpin and Bruker AXS for mass spectrometry, NMR, and X-ray
crystallography technologies, and Aurora BioSciences, now a wholly
owned company from Vertex Pharmaceuticals, to advance AffiniumÕs internal
programs. The Company is continuing to forward integrate its capabilities
to becoming a leading structure based drug design and development
company. |
Life
Sciences/Chemical Agilent is a leading provider of life sciences and
analytical instrument systems to scientists in life sciences, pharmaceutical,
environmental and chemical industries, worldwide. The company offers
scientists the range of instruments, systems and services needed for
success in acquiring and interpreting genetic and chemical information
- from sample handling, to analysis to data management and reporting.
We are committed to providing superior standards-based technology,
designed for maximum productivity, cost effectiviness and ease in
complying with regulatory requirements. |
 The
next generation of healthcare will be built on understanding the genetic
basis for disease. Amersham Pharmacia Biotech has the expertise and
vision to help researchers in industry and academia to turn the promise
of this molecular medicine into reality. Our biotechnology systems,
(instruments, reagents and software) products and services are used
in gene and protein research, drug discovery and development, and
biopharmaceutical manufacturing. |
 Applied
Biosystems announced the formation of a center for proteomics research
at its PerSeptive Biosystems Division. The Proteomics Research Center's
mission is to define novel tools for proteomics, focus on the advancement
of the science of proteomics, and develop practical application-based
systems for the fields of research, drug discovery and development,
and health care. |
Aptagen
Aptagen,
Inc. is a protein sciences company specializing in genetic and proteomic
manipulation through the use of our Gene Forge and Protein Genesis
technology platforms. Aptagen's Gene Forge designs and builds custom
synthetic genes or double stranded DNA of any size, optimizes the
codon usage for maximum protein expression in the organism of your
choice, is able to selectively modify a gene for proper folding and
activity in a foreign host, and performs a number of other manipulations
to facilitate efficient and cost effective research and product development.
Protein Genesis is a highly advanced intracellular form of Directed
Molecular Evolution which allows us to alter the actual structure
and function of a protein of interest in order to increase primary
activity and eliminate side effects of protein therapeutic drug products.
|
A Canadian
Biopharmaceutical company with a cutting-edge technology in Functional
Proteomics. Aurelium is identifying and developing novel Lead targets
and drugs for the treatment of cancer and infectious diseases. Aurelium
has several patented technologies that are used for identifying Lead
targets for drug development and developing novel anticancer and antimicrobial
drugs. Aurelium's technology is based on a breakthrough in the understanding
of protein-protein interactions. This technology is expected to revolutionize
the process of identifying targets for drug development in the pharmaceutical
industry. |
 Astex
is a structure-based drug discovery company pioneering the use of
high throughput X-ray crystallography (HTX®) technology for the
rapid identification of novel drug candidates. HTX®Êtechnology
is part of an innovative drug discovery platform that integrates all
aspects of structure-based research, including protein production,
crystallization, structure determination, bioinformatics and computational
and medicinal chemistry. The discovery of novel drug leads at Astex
is driven by the company's unique structural screening approach that
utilizes protein crystal structures to discover and optimize lead
compounds. Astex's Pyramid™ approach to lead discovery utilizes
structural screening for the detection and optimization of small-molecule
fragments. Many thousands of these fragments are structurally screened
using the company's proprietary X-ray crystallography technologies.
This results in a powerful process for rapid structure-based lead
generation. Astex is using this approach to identify novel drug leads
for proprietary and public domain targets. |
 AxCell
is engaged in the research and development of novel biopharmaceutical
products using its growing portfolio of functional proteomics solutions
and collection of proprietary signal transduction pathway information.
Through the systematic and industrialized measurement of protein-to-protein
interactions, AxCell is assembling ProChart™, a proprietary database
of signal transduction pathway information. ProChart™ currently
includes pathway information for protein domain families relevant
in a number of therapeutically important classes of molecules including
growth factors, receptors and other potential protein therapeutics
or drug targets. AxCell's database content and functional proteomics
tools are available on a non-exclusive basis to biotechnology, pharmaceutical
and academic researchers. AxCell is expanding and accelerating its
research activities to further elucidate the role of novel proteins
and pathways in ProChart™, through both external collaborations
and internal data mining. |
 Beyond
Genomics (BG) is revolutionizing drug discovery with a novel Systems
Biology approach. The BG approach literally goes 'beyond genomics'
to analyze complex clinical samples at a biological systems level.
More specifically, we analyze and integrate data at the gene/transcript,
protein and metabolite levels using our proprietary BioSystematics™;
technology. The resulting systems biology information allows BG to
create knowledge that advances pharmaceutical R & D by providing new
insights into the molecular mechanisms of health and disease. Our
discovery efforts focus on applying this knowledge to the development
and discovery of novel therapeutics to treat human disease. Our technologies
and unique approach are applied throughout the drug discovery and
development process. The broad utility of BG's approach allows us
to leverage our capabilities; transcriptomics/genomics, proteomics
and metabolomics, across a portfolio of applications. BG's BioSystem
Marker™; identification enables us to bridge the pharmaceutical
innovation gap by uncovering new pathways for therapeutics-filling
pipeline shortfalls and meeting unmet medical needs. Beyond Genomics
was founded in November 2000 by thought leaders in systems biology
from Harvard, Purdue, Indiana, and Leiden (The Netherlands) Universities.
We currently operate labs and occupy office space in Waltham, MA,
and support researchers in The Netherlands. |
 Biacore
is the acknowledged global leader in the development, manufacture
and marketing of innovative and unique products to detect and monitor
biomolecular binding. BIACORE is able to add a new dimension to the
world of Proteomics. We are helping to find new binding partners for
target molecules. Simultaneously we give information about their binding
characteristics and providing purified sample for identification by
mass spectrometry. |
BioBridge Computing AB is a company that develops and markets intelligent
software in the field of bioinformatics. Our current activities are
focused on proteomics where we are developing products for data analysis
for mass spectrometry. |
 Biomax
Informatics AG and Roche announce ProteoExpert speeds up protein research.
ProteoExpert RTS E. coli HY is a new Internet-based information service
from Roche Diagnostics. It's designed to assist scientists working
in the field of protein research with the Rapid Translation System
(RTS), Roche's platform for cell-free protein synthesis. The ProteoExpert
was developed in co-operation with Biomax Informatics AG, Martinsried,
Germany and will reduce costs and add considerable efficiencies to
cell-free protein synthesis. |
 The
ProteomeWorks system is an integrated set of tools and technologies
that enables protein function discovery. Innovative new tools for
sample preparation, 2-D electrophoresis, staining, imaging and image
analysis, spot excision, automated protein digestion, mass spectrometry,
and bioinformatics create a seamlessly integrated, high-throughput
proteomics platform. |
 BIOSITE'S
IMMEDIATE RESPONSE DIAGNOSTICS™ TECHNOLOGY is based on proprietary
advances in several core scientific and engineering disciplines, including
antibody development and engineering, analyte cloning and synthesis,
signaling chemistry and micro capillary fluidics. The Company has
utilized its core technologies to develop two distinct product platforms:
The Triage Panel for qualitative visual readings and the Triage Meter
System for quantitative measurements. The Company's products are designed
to measure either a single analyte or multiple analytes simultaneously
and to allow for the qualitative or quantitative analysis of various
samples, including urine, serum, plasma, whole blood and stool. Both
of the product platforms are designed to provide rapid results, ease
of use, high analytical accuracy and the capability of performing
multiple analyses in a reliable testing device. |
 Biovation
is a UK-based biotechnology company using its proprietary DeImmunisation
technology to deliver a new generation of substantially non-immunogenic
therapeutic antibodies and proteins. Biovation works with its partners
in the biotechnology and pharmaceutical fields to eliminate immunogenicity
in a broad range of antibody and protein therapeutics through the
application of its groundbreaking DeImmunisation technology.Ê All
antibodies, even humanised and fully human, can potentially trigger
an immunogenic response when administered to patients.Ê DeImmunisation
of antibodies eliminates that risk without compromising efficacy.
|
 Bio-Xtal
is centred around three main poles of activity: SOPNET™ (Soluble
Protein Network). The aim of SoPNet is to upgrade the value of new
or old structures resolved by Bio-Xtal's European academic laboratory
partners. Industrials interested in these structures can request services
from Bio-Xtal (complex studies, protein production) for the subjects
proposed in the catalogue. A percentage of the turnover generated
by the upgrading of these "academic" structures is redistributed
to our partner laboratories to finance the resolution of new structures.
MEPNET™ (Membrane Protein Network): Bio-Xtal has engineered the
creation of a unique, global research consortium to study 100 G-Protein
Coupled Receptors (GPCRs). The objective of this programme is to overcome
the problems linked to GPCR production, purification, extraction,
solubilisation, stabilisation and crystallisation. This consortium
currently boasts the participation of over 40 major pharmaceutical
and biotech companies, as well as 4 European academic laboratories.
The MePNet programme was launched in September 2001. For more information,
you could visit the web side of the program www.mepnet.org. Providing
Structural Services: One of the company's aims is to provide a high
quality of technology to health care specialists in the field of structural
biology through our high throughput crystallography platform. We are
able to undertake all the different stages of molecular biology and
biochemistry, up to structure resolution. These services focus on
new structure resolution and protein-inhibitor complex studies. |
 A
global company focused on the advancement of all of the sciences supported
by mass spectrometry, with a commitment to finding new and more powerful
uses of MS technology wherever possible. Supplies the PROTEUM Series
of products which is focused on the determination of crystallographic
structures of proteins and other biological macromolecules. Don't
forget, Bruker
Daltonik Germany has a terrific website. |
|
 Caliper
is a leader in lab-on-a-chip technologies. We develop, manufacture
and sell our proprietary microfluidic LabChip® systems to pharmaceutical
and other companies. We believe our LabChip systems can assemble
the power of entire laboratories full of equipment and people. Our
LabChip systems miniaturize, integrate and automate many laboratory
processes, and put them on a chip that can fit in the palm of a
child's hand. Each chip contains a network of microscopic channels
through which fluids and chemicals are moved in order to perform
experiments. We believe our LabChip systems represent a revolutionary
advance in laboratory experimentation.
|
 Caprion
is a drug discovery company applying proteomics to discover and develop
innovative products for the diagnosis and treatment of disease. With
its integrated technology platform and unique expertise in cell fractionation,
Caprion uncovers the proteomic changes involved in disease, and delivers
novel targets to develop effective new treatments for cancer and other
diseases. Caprion and its pharmaceutical industry partners then use
these targets as the basis for new diagnostics or drugs, the earliest
being diagnostic products for Mad Cow Disease and variant Creutzfeldt-Jacob's
Disease (vCJD). Caprion's goal is to become a fully-integrated drug
discovery company offering a broad suite of resources in custom discovery
research programs. |
 Celera
Genomic's mission is to become the definitive source of genomic, proteomics
and related biological and medical information. |
 Cellzome,
a leader in the field of functional proteomics, uses its proprietary
technology platform to characterize cellular protein complexes. Protein
complexes are responsible for biological activity and are the actual
molecular targets of drugs. Cellzome is developing protein interaction
and pathway maps obtained under varying experimental conditions. This
information will describe the molecular context for identified targets
and provide the basis for target and lead validation. Cellzome believes
that this approach will enable better understanding of the mode of
action of existing and potential drugs, creating the opportunity to
develop second generation drugs with higher efficacy, specificity
and safety profile. |
 Ciphergen
Biosystems, develops, manufactures, sells, and services ProteinChip¨
Systems and related products that discover, characterize and assay
proteins from native biological samples. Ciphergen customers include
many of the largest pharmaceutical and biotechnology companies worldwide,
as well as government agencies, research institutions, and universities.
Working with customers to develop new products and applications, Ciphergen
is becoming a leader in biomarker discovery, assay development and
characterization. |
 Cognia
is a developer and distributor of knowledge-based products that facilitate
the use of genomic, proteomic and cellomic/physiological information.
Cognia provides integrated suites of high-quality, annotated databases,
cutting edge bioinformatic tools, and associated consulting services
to accelerate drug discovery and basic research. |
 Compugen
develops and markets platforms, tools and products that accelerate
post genomic research, the advanced study of proteins and protein
pathways, and drug target discovery.
|
 CuraGen
combines genomics expertise with integrated, industrialized technologies
to rapidly discover genes, ascertain their function, and categorize
them as potential protein drugs, antibody targets, and small molecule
drug targets. Scientists and engineers at CuraGen have developed a
suite of integrated functional genomic technologies and have combined
these with comprehensive disease programs to gain an in-depth understanding
of how genes and their related proteins function in the context of
disease. |
DECODON
GmbH is a bioinformatics company that was founded to develop software
for the modern Life Sciences. Its bioinformatics tools are helping
scientists to generate knowledge from the massive amounts of data
that are accumulated by recent methods in global functional genomics.
The company brings together specialists with diverse backgrounds from
Molecular Biology, Computer Science and Mathematics. Software development
at DECODON is driven by the needs of leading researchers in the field
of functional genomics and realized by using advanced methods from
various areas of Mathematics and Informatics. DECODON's first product,
Delta2D, a program for fast analysis of 2D electrophoresis images,
proves the efficiency of this approach. |
 Drug
discovery is under increasing pressure to deliver increasing numbers
of development candidates to fill the corporate drug pipeline. This
means that there is an urgent need for high quality lead compounds
in order to drive the provision of candidates for pre-clinical development.
This problem is compounded by the ever-increasing number of putative
therapeutic targets coming out of Genomic and Proteomic research.
Our computational and medicinal chemists work closely together utilizing
our proprietary suite of programs in the design of novel scaffolds
that interact optimally with the chosen target binding sites. These
scaffolds are further elaborated with appropriate reagents inÊsilico,
to produce virtual combinatorial libraries that can be readily synthesised.
It is the close collaboration between Computational, Medicinal and
Combinatorial Chemists that makes this process so efficient. |
 Our
comprehensive computational chemistry and structural biology services
help you get the most from your synthesis and screening programs.
We believe that optimal lead discovery and optimization is the result
of a continual thorough analysis and understanding of all relevant
structural, chemical, and biological information. Our proprietary
methods enable this critical understanding of the target, its ligands,
and the target-ligand relationship. When the structure of the target
is known we employ proprietary structure based design methods. Our
Token™, technology is used to characterize and compare protein
surfaces. Through this analysis we can design for affinity and specificity
reducing the likelihood of undesirable crossreactivity and late stage
clinical failure. Using SurFlex™ Dock and Refinery™ we are
also able to rapidly perform and analyze virtual screening experiments
to identify meaningful leads for biological screening. When the structure
of the target is not known, we employ proprietary ligand based design
methods to design and rapidly analyze the results of high throughput
screening experiments. Initial screening compounds may be selected
to be similar to known ligands, or maximally diverse when little or
no ligand information is available. Screening results are rapidly
analyzed using Support Vector Machine algorithms which are able to
determine which features of a molecule correlate best with activity,
and those which correlate with inactivity. This knowledge is then
used to formulate a Structure Activity Relationship which guides compound
synthesis for follow on screening. |
 Proteome,
Inc. and DoubleTwist, Inc. today announced a partnership to provide
data from Proteome's BioKnowledge Library through the genomic research
portal DoubleTwist.com. Proteome's BioKnowledge Library provides extensive
biological knowledge of genes and proteins across a wide variety of
species. |
 Eprogen
introduces ProteoSep™, a novel protein mapping technology and
a new way to analyze complex protein mixtures. ProteoSep™ is
an all-liquid phase alternative to 2D PAGE that uses high performance
liquid chromatography (HPLC) to produce high resolution 2D maps of
very complex protein systems such as whole cell lysates. HPLC and
HPLC/MS have already proven very important for complex peptide analysis
in Proteomics. ProteoSep™ now brings the power of HPLC to the
mapping and liquid -phase fractionation of intact proteins from complex
systems to provide scientists with an important new tool in the area
of Proteomics. |
 EUROPROTEOME
applies state-of-the-art, convergent gene expression technologies
- in particular proteomics and transcriptomics to human epithelial
cancers (e.g. colon or lung cancer) in order to identify cancer-specific
protein expression patterns (targets / markers) suited for clinical
applications. After characterizing and validating these identified
targets, EUROPROTEOME offers these targets for co-development agreements
with industrial clients and marketing partners. |
 GeneData
is a global leader in the development of bioinformatics systems and
related services in the functional genomics arena. We deliver innovative
computational solutions for the management and intelligent analysis
of large quantities of structurally complex biological data, generated
by genome sequencing, microarrays, protein expression profiling, metabolic
profiling and high-throughput screening. Our partners include major
life-sciences organizations and some of the world's most prestigious
research institutions. We strive to help our partners maximize their
return on investment from costly technologies and gain a deeper understanding
of underlying biological processes for advancement of their own research
and product development. Founded in 1997, GeneData has grown to a
team of around 70 experts from diverse fields including molecular
biology, biochemistry, computer science, (bio)physics, mathematics
and statistics. Our growth continues as we recruit the best people
for developing and applying in-silico methods for functional genomics
problems. |
|
 GeneFormatics
Incorporated, a world leader in structural proteomics, focuses on
providing novel protein function and structure information to pharmaceutical,
biotechnology and agrochemical companies to accelerate the discovery
of new medicines and other useful products. GeneFormatics applies
its integrated, "function first," high throughput proteomics platform,
which combines in silico technologies, NMR spectroscopy, X-ray crystallography
and bioassays, on genomic scales to assign protein function and
determine protein structure.
|
GeneBio is committed to providing quality databases, software tools
and services to the Life Science industry particularly in the field
of proteomics. We are the exclusive worldwide representative for the
licensing to commercial institutions of the proteomics databases and
software tools which are developed and maintained by the Swiss Institute
of Bioinformatics (SIB). |
 GeneProt's
goal is to become the leader in the discovery, identification and
characterization of proteins and their functions for major disabling
or life threatening diseases. GeneProt has successfully combined the
elements of science, technology and management to ensure its success.
GeneProt's team of cutting-edge scientists, those behind many of the
breakthroughs that define the current state of proteomic knowledge,
is supported by state-of-the art equipment, including one of the industrial
world's most powerful computer systems, management expertise in the
biotech field and a number of strategic partnerships. |
 Genomic
Solutions is a leader in total integrated solutions for both genomic
and proteomic research. Genomic Solutions was one of the first in
the industry to implement the entire process of proteomic analysis
and gene expression analysis. The result is a unified family of products
that work together for precise, convenient and efficient proteomic
and functional genomic research. Combined, these technologies can
shed more light on disease processes than either can alone. |
 Glaucus
Proteomics is a research and development organization which has developed
a cost-effective process (SGP / array based proteomics) for the identification
and characterization of disease-specific proteins. This process will
greatly improve the understanding of disease processes, thereby facilitating
the cost-effective development of new drugs and disease prevention
strategies. To employ peptide, protein and antibody arrays as an integrated
approach to delivering quantitative information on the antigenic diversity
and abundance of the entire Human Proteome in health and disease.
This will facilitate large sample cohorts, highly reproducible results,
truly parallel analyses and proteomic coverage beyond that possible
by traditional technologies. Higher quality targets for the development
of intervention strategies are expected from analysis of the 'molecular
workhorses' within living systems, i.e. the proteins. An immediate
application of our technology platform will be implementation of improved
methodologies for reducing the likelihood of unpredicted toxic side
effects going unnoticed during lead development within the pharmaceutical
industry - facilitating the 'kill early, kill cheap' philosophy. Our
proprietary array-based technologies will also be employed to go beyond
that currently possible for reproducible proteomic analysis of bacteria
and lower eukaryotes in the search for improved vaccines against life
threatening diseases. |
 GPC
Biotech AG is a leading transatlantic genomics-driven drug discovery
company with a broad integrated technology platform that is unparalleled
in Europe. A number of proprietary genomics, proteomics and drug discovery
technologies help to accelerate the process of drug discovery and
development. Alliances with leading global pharmaceutical companies
validate GPC Biotech's technologies and generate revenue streams that
help fund the Company's internal drug discovery projects which are
focused on oncology, infectious diseases and immunology. GPC Biotech
has a broad intellectual property position. In March 2000, the acquisition
of the drug discovery company Mitotix, Inc. (now GPC Biotech Inc.,
Waltham/USA), which has world-leading expertise in cell cycle research,
significantly accelerated the Company's forward integration. The combined
Company realizes a common and powerful vision of integrated genomics-
and proteomics-based drug discovery throughout the entire process
of drug discovery, from target discovery to the clinic. |
 Hybrigenics
is a leader in Functional proteomics, the study of the role and functions
of proteins in cellular pathways. Hybrigenics thus addresses the major
current need of the pharmaceutical industry, validation of high quality
therapeutic targets allowing an improved success rate of novel compound
development. The Company has developed integrated biological experiment-based
and in silico-based technology platforms that allow identification,
selection, prioritization and validation of drug targets. Hybrigenics'
strategy is to use these platforms on an industrial scale to discover
and validate novel targets for biopharmaceutical companies and to
build a pipeline of proprietary biomarkers, small molecules and antibody
drug products. |
 IBM
Life Sciences is dedicated to rapidly bringing leading-edge technology
out of the laboratory and into the marketplace for customers and Business
Partners in the fields of pharmaceutical research, biotechnology,
genomics, proteomics, health care, and academic research. |
HTS Biosystems' Proteomatrix™ Solution requires a number of different
technologies. HTS Biosystems has assembled an impressive combination
of proprietary technologies to allow us to offer the best tools to
meet the specific needs of different segments of the proteomics market.
The solutions we provide for our customers are targeted to their needs
and not limited by our technology portfolio. |
 Proteome
BioKnowledge® Library Now part of the Incyte family of products,
the Proteome BioKnowledge Library is a powerful collection of databases
focused on the compilation of available protein information. Using
our proprietary processes, we comb through relevant biological literature
for curation into our products. The data are then presented in an
easy to use format that offers enhanced flexibility and powerful time
savings over traditional library research. Access to thousands of
independent research results offers the competitive advantage of reduced
library research time and faster progression through discovery pathways.
|
 InforMax
is a leading global provider of bioinformatics software solutions
for the analysis and interpretation of genomic, proteomic and other
biomolecular data. InforMax, founded in 1990 by Dr. Alex Titomirov,
enables over 31,000 researchers worldwide to achieve greater insights
into genetic function through biological data mining and integrated
genomics analysis. |
 Inpharmatica,
a leading informatics-driven drug discovery company, applies information
from its platform technologies on the relationships between the structure
and function of proteins to the discovery of novel drugs. |
Kendrick
Labs
Kendrick Labs performs protein electrophoresis as a service for academia,
federal institutions and industry. Our mission is to help clients
solve protein problems quickly and economically, especially problems
which require 2-dimensional electrophoresis. We started in 1981 in
Madison, WI catering to scientists at the university. Now with the
advent of low-cost express mail, fax, 800 numbers and e-mail our 2D
gel service functions nationwide; we receive samples and return results
to New York and Los Angeles as fast as labs based in these cities.
Furthermore, turnaround to the UK is nearly as fast as to LA because
we now understand US customs. |
Large Scale Biology Corporation (LSBC) is one of world's leading companies
dedicated to the discovery, analysis, manufacture and commercialization
of proteins Ñ the molecules at the business end of biology. LSBC's
activities are built around an integrated suite of ultra-sensitive,
industrial-scale technologies created to realize the full commercial
and pharmaceutical potential of biology. LSBC's proprietary technologies
radically extend the power of genomics. Whereas traditional genomics
companies concentrate on deciphering genetic information, LSBC goes
further, directly analyzing, manipulating and manufacturing the proteins
that the genetic information encodes. Proteins are at the heart of
all biological processes, and LSBC's unique protein-focused technologies
have placed the company at the forefront of the drive to bring twenty-first
century biology to the marketplace. |
 LLG
is an integrated functional genomics and proteomics company, focused
on the therapeutic area of neurodegenerative diseases, whose mission
is to find the Lay Line towards the discovery of drugs for Alzheimer's
and other neurological diseases, leveraging on a unique protein knock-out
technology platform. |
 The
Bridge Between Genomics and Medicine Will Be Built on Proteomics.
Traditional methods of drug development involve screening thousands
of chemical compounds. Compounds are first tested in cell culture,
and those that show the desired activity are tested in animal models.
Finally, the few compounds that pass animal testing are taken into
human clinical trials. Only about one in 10,000 chemical compounds
makes it through this laborious process. In contrast, LifeSpan's gene
localization technologies help pharmaceutical companies to rapidly
identify the most promising drug targets. By localizing proteins and
messenger RNAs within human tissue samples, LifeSpan can determine
when and where individual genes are expressed - down to the subcellular
level. By reducing the number of potential drug targets to genes for
which expression is altered with disease, new drugs can be developed
more quickly and cost-effectively. Sequencing the human genome was
a milestone for science. But it was just the first step in a longer
journey toward understanding disease processes. That's where LifeSpan
helps. |
 LumiCyte,
Inc. is a biotechnology company focused on the discovery and routine
delivery of powerful new medical knowledge. LumiCyte uses its patented
Protein BioChips, BioChip Readers and informatics technologies to
enable the detection of disease earlier than ever before, more accurate
classification of disease type, better monitoring of disease progression
and more accurate and cost-effective monitoring of individual patient
response to therapy. LumiCyte collaborates with leading universities,
medical centers of excellence, and partners with companies to advance
the medical usefulness of its integrated protein separation, mapping
and analysis capabilities. LumiCyte's objectives are to enable and
accelerate successful drug development efforts and to help create
the diagnostic and therapeutic capabilities necessary to deliver individualized
medical care. |
Lynx will apply its genomics, genetics, and proteomics technologies
to accelerate the pace, broaden the scale, enhance the quality, and
lessen the cost of the discovery and development efforts of customers
in the pharmaceutical and agricultural biotechnology industries. |
 Matritech
is a leading developer of proteomics-based diagnostic products for
the early detection of cancer. Using its patented proteomics technology,
Matritech has identified proteins correlated with breast, bladder,
prostate, cervical and colon cancers. Matritech is one of the first
companies to successfully employ proteomics to create diagnostic products.
The company holds one of only two FDA product approvals for the initial
detection of cancer. The FDA-approved NMP22 bladder cancer test is
currently used by urologists. In addition, the company has a promising
blood-based breast cancer test, NMP66, in clinical trials. Initial
research on a prostate cancer marker identified by Matritech scientists
shows the maker to be more accurate than the widely-used PSA test.
NMP technology was licensed exclusively to Matritech from the Massachusetts
Institute of Technology. |
This site features Mascot, a powerful search engine which uses mass
spectrometry data to identify proteins from primary sequence databases.
To assist you, the help text for Mascot forms a substantial knowledge
base concerning protein identification by MS. |
 MDS
Proteomics' is a proteomics-based drug discovery company and is forming
a small number of broad collaborations with leading biopharmaceutical
companies. The company's goal is to help its partners increase their
productivity through rapidly identifying, triaging and selecting more
functionally annotated drug targets in disease. MDS Proteomics applies
its proprietary proteomic approaches in novel ways, in order to increase
the probability of clinical success of targets and reduce the time
associated with its partner's drug discovery and development processes.
This will lead directly to the design and development of more effective
and safer medicines, faster. MDS Proteomics has developed a fully
automated, large-scale proteomics' platform that seamlessly fuses
ultra-sensitive mass spectrometry systems, pathway biology, high-performance
supercomputing, computational design and drug screening technology.
MDS Proteomics employs over 200 people in its next-generation proteomics'
facilities in Europe and North America. The company focuses on target
discovery and development for both antibody and small molecule therapeutics
and presently has a number of candidate targets in pre-clinical discovery.
|
 Protein
structures identified through MediChem's proprietary proteomics services
and technologies are the basis for the identification of novel drug
targets. Our proteomics and computational chemistry offerings are
key components in bridging the gap between genomic information and
chemistry services necessary to identify new lead compounds with the
most desirable action. |
 MelTec
is a pioneer in topological proteomics optimising the drug discovery
process in the post-genomic era. MelTec represents the only company
with a proprietary technology capable of performing completely automated
proteomics characterization at the single cell level, for an unlimited
number of proteins. The company's approach aims to understand and
decipher cellular function and dysfunction by determining the situation
of protein networks in time and space in every intact cell. MelTec's
topological proteomics technology facilitates and greatly speeds the
pre-clinical stages in the drug development process and the identification
of biomarkers for diagnostic purposes. MelTec's unique proteomics
technology positions the company to become a major contributor to
this new post-genomics era of drug development. |
 Myriad
Genetics Inc. is a biopharmaceutical company focused on the development
of therapeutic and diagnostic products using genomic and proteomic
technologies. The Company's emphasis on product development is demonstrated
in its major business components: Therapeutic product development
in important disease areas. Identification of disease-causing genes,
as potential drug targets, for major pharmaceutical company partners.
Disease pathway discovery through ProNet® and ProSpec® proteomic
technologies to isolate drug targets for development. Molecular diagnostic
testing for inherited risk of disease. Use of high-throughput DNA
sequencing to reveal the genomes of important animal, plant and microbial
species Myriad has two wholly owned subsidiaries Myriad Pharmaceuticals,
Inc., which develops and markets therapeutic compounds, and Myriad
Genetic Laboratories, Inc., which develops and markets proprietary
molecular diagnostic services and has introduced products in the fields
of predictive medicine and personalized medicine. The Company has
established strategic alliances with Bayer, Eli Lilly, Hitachi, Pharmacia,
Novartis, Roche, Schering AG and Schering-Plough. |
| NEUROLAB
your Research Partner is also dedicated to your discovery, preclinical,
clinical and drug development programs. Through its worldwide network
of research expertises it will help you progress faster in your programs
in the fields of Neurosciences and Oncology. Functional Proteomics
Programs to perform biomarkers discovery (profiling, identification,
characterization and validation). |
NextGen Sciences is a fast track technology development company specialising
in the fields of genomics, transcriptomics and proteomics. The company
integrates information at the level of the gene, gene transcript and
protein, developing technologies which include hardware, software
and the associated biochemistries to create, enhance and further facilitate
scientific and drug discovery knowledge and processes. The company's
business model is to generate early revenues through out-licensing
elements of their technology to key corporate partners who are well
renowned organisations with a global infrastructure in sales, marketing,
service and technical support. Recently, NextGen Sciences announced
their corporate partnership agreement with PerkinElmer Life Sciences
resulting in the introduction of the ProteinArray Workstation™,
the first fully automated system for processing protein microarrays,
which was developed using NextGen Sciences' derived intellectual property
and know-how. Under the terms of this agreement, PerkinElmer Life
Sciences will manufacture and have exclusive worldwide distribution
rights for the system. NextGen Science platform technologies are developed
by internally-driven research programmes, via collaboration and partnerships
with other companies and key academics with complementary skill sets.
|
 Established
in 1989, Nonlinear Dynamics is a leading worldwide provider of Bioinformatics
solutions to the life science industry. Our innovative product portfolio
comprises high-quality analysis and data mining tools for 1D and 2D
electrophoresis gels and microarrays, the core technologies of genomics
and proteomics. Product Portfolio From high-volume, broad-based projects
to high-value, specialist studies, our products fulfil scientific
needs using leading-edge software tools. The Company product range
is built around the industry-standard Phoretix image analysis and
database software for 1D and 2D electrophoresis gels and high-throughput
arrays. A recent addition has been Progenesis, a revolutionary product
for the analysis of high-throughput 2D gels used in major proteomics
projects. Also in the pipeline is Progenera, a product for the integration
and in-depth interrogation of biodata from proteomics and genomics
studies, and Accelerator, a product to extend the scalability of our
software solutions. ISO 9001 / TickIT accreditation gained in 1998
verifies and maintains the high quality of design, development and
production processes implemented at Nonlinear. |
 We
are a leader in the emerging field of proteomics, the comprehensive
study of proteins. We have successfully integrated proteomics with
genomics to create an innovative, proprietary drug discovery platform
that allows the systematic separation, identification and characterisation
of proteins on an industrial scale. Our goal is to use that platform
to enable the development of a new generation of break-through products
by: building a pipeline of proprietary small molecule and antibody
drug and diagnostic products based on a portfolio of patent applications
relating to, or to the use of, disease-associated proteins; and providing
proteomics services and data to the pharmaceutical and life sciences
industries. |
 Phylos
is leading the development of an integrated drug discovery program
based on its powerful combinatorial biology platform, PROfusion™
technology. The platform is being broadly applied to the high throughput
discovery of high affinity and highly specific binding proteins for
research, microarray, and biotherapeutic applications. |
 Versalinx
Protein Microarray Technology--an open-platform array system designed
exclusively for proteins--is universal, versatile, rapidly optimized,
and easily automated. Versalinx Technology utilizes a synthetic chemical
affinity chemistry, based upon the reversible complexation of phenyl(di)boronic
acid (P(D)BA) with salicylhydroxamic acid (SHA). The system is compatible
with common spotting and detection instrumentation for rapid and efficient
implementation. |
 ProMetic
develops synthetic organic entities known as Mimetic Ligands™,
which are designed to effect very specific interactions with proteins.
Of particular interest is ProMetic's involvement in genomics, proteomics
and monoclonal antibodies where chemical ligands are used not only
to purify promising therapeutics, but can become lead compounds for
drug discovery programs as protein/peptide mimetic. To date, ProMetic
has developed and manufactured large scale Mimetic Ligands™ for
a wide range of therapeutics derived from plasma, recombinant or transgenic
sources. |
 The
NanoES sources manufactured by Protana for various electrospray mass
spectrometers follow the working principles described by Matthias
Wilm and Matthias Mann at the European Molecular Biology Laboratory
(EMBL), Heidelberg, Germany. |
 ProteEx
is a commercial consulting proteomics laboratory specializing in the
application of proteomics to medicine. We offer a suite of services
that meets the full scope of protein analytical needs for the post-genomic
era, uniquely designed to provide full service proteomics for companies
and institutions engaged in pharmaceutical, diagnostic, and natural
products research, development, and commercialization. Our customers
require top-notch, sophisticated, tough, high-end protein biochemistry
applied to well designed medically-related projects. We perform on
a fee for service basis and do not require IP or royalty participation
in exchange for services. At the discretion of the client we also
consider partnering relationships. We also develop our own IP. |
Protein Pathways is a privately held biotechnology company, founded
in 1999, that is a leader in the development of algorithms that can
be applied to the functional interpretation of sequenced genomes.
Our proprietary system of pathway elucidation is called the ProMaps™
discovery system. While most comparative genomics analyses are based
almost exclusively on similarity searches that infer only limited
aspects of biological function, the ProMaps™ discovery system
can predict gene function, place newly discovered genes in existing
pathways and elucidate interactions between pathways. In other words,
by using the ProMaps™ discovery system it is possible not only
to predict the biological classification of a gene product, but to
also gain insight into interacting proteins, the nature and identification
of probable substrates, and the biological context of the associated
pathway. The company has established the discovery of molecular interactions
as its core competency because of the firm belief that placing genes
in existing pathways and understanding the network interactions between
pathways will inevitably lead to improved methods that facilitate
the small molecule drug discovery process. |
 Proteologics
is a drug discovery and development company engaged in sub-cellular
proteomics that utilizes proprietary protein extraction, separation
and tagging methods to discover novel membrane associated protein
drug targets. The company's primary focus is on the discovery of disease
relevant membrane proteins, the most valuable but difficult to separate
group of protein drug targets. |
 Proteom
is a dedicated bioinformatics company which is defining the rules
that govern protein-protein interactions at the amino acid level -
the proteomic code. By coupling these rule sets with an understanding
of associated biology, Proteom is uniquely able to: design peptides
of around seven amino acids, predicted to bind with specific regions
of a protein; identify protein binding sites on a given protein; and
predict protein-protein interactions. Proteom's technology enables
the intelligent selection of targets and ligands in silico before
entering costly drug discovery programmes in the laboratory. |
 The
Proteome Factory AG is a modern biotech company. Scientific research
focuses on neurodegenerative disease and oncology. The proteomic key
technology platform enables key proteins in emerging disease and biomarkers
for the disease state to be rapidly and efficiently identified. Target
proteins are then validated, initially through the use of virally
and stably transfected cell lines and, at a later stage, transgenic
and knock-out technologies are applied. This combination of validatory
techniques enables the Proteome Factory AG to distinguish more relevant
target proteins for a specific disease process, highlighting possible
therapeutic targets. The main task of the Proteome Factory AG therefore
is the development and validation of new therapeutic drugs with a
particular focus on neurodegenerative disease and cancer. |
 Bought
by Incyte Genomics. Proteome, Inc. is dedicated to reducing the complexity
of the information landscape by providing researchers in the life
science industry with an integrated biological knowledge system that
combines experimental protein knowledge captured by comprehensive
human curation, the latest genomic and functional genomic datasets,
and powerful software tools to reveal the connectivity of biological
knowledge across the species. |
 Proteome
Sciences is a leading company in proteomics, a new scientific discipline
which enables correlations to be drawn between the range of proteins
produced by a cell or tissue, and the initiation or progression of
a disease state. Proteomic research permits the identification of
new protein markers for diagnostic purposes, and of novel molecular
targets for drug discovery. Proteome Sciences is applying its proprietary
proteomic technologies to identify novel protein markers of disease.
The levels of detection obtained achieve more than 10,000 times greater
sensitivity than existing methods. These discoveries will be further
developed and commercialised as diagnostic or therapeutic products
through external partnering arrangements. Proteome Sciences is headquartered
in Cobham, Surrey, UK, with research facilities located in London,
UK (at Harefield Hospital), and in Raleigh-Durham, North Carolina,
USA (at Intronn LLC, a US subsidiary). Proteome Sciences' research
capability is significantly expanded through exclusive collaboration
agreements with over 20 leading academic research establishments across
the world. This work has resulted in a large amount of useable data.
|
 Proteome
Systems is dedicated to the development of proteomics technology,
to the discovery of biomarkers and drug targets, and to proteomic
bioinformatics. Established in 1999, Proteome Systems has quickly
grown to become one of the world's major forces in proteomics. Proteome
Systems is headquartered in Sydney, Australia and has premises in
the Boston area in the United States. Both sites have more than 20,000
square feet of office and/or laboratory space. With over 70 staff,
more than half which hold PhDs, Proteome Systems has developed an
integrated suite of novel technology to make the world's first integrated,
high-throughput platform for proteome analysis. This platform, ProteomIQ™
currently deployed on a large scale in the Sydney laboratories and
soon to be deployed in many sites around the world, is massively accelerating
Proteome Systems' discovery research. Proteome Systems Ltd is an Australian
private company. Its shareholders include its founders, senior management
and other private corporations. |
 ProteomTech,
Inc., a new biotechnology company specializing in protein refolding,
has developed a "universal" refolding procedurefor purifying proteins
expressed in E. coli as inclusion bodies. The procedure will be used
for high-throughput purification of recombinant human proteins and
other proteins of therapeutic interest for commercialization.
|
 ProteoMetrics,
LLC is a bioinformatics company that develops innovative software
to rapidly identify and characterize proteins. The company developed
out of an academic effort to more effectively utilize proteomic research
and has now expanded into the commercial sector. Currently, a major
focus of our activity is the development of an advanced intranet framework
to support large-scale, high-throughput proteomics projects. |
 Protiveris,
Inc., in operation since March 2000, is the result of a broad collaborative
effort among leading scientists seeking to merge silicon micro-fabrication
with biology to advance technology beyond the genomics revolution.
The name Protiveris means "Truth in Proteins." Protiveris' mission
is the development of discovery and diagnostics technologies that
enable life science professionals to understand biological function
at the protein level. Protiveris is strategically positioned at the
crossroads of biology, chemistry and physics with a particular emphasis
on bionanotechnology. Patented silicon technologies under development
at Protiveris have broad applications including proteomics, molecular
diagnostics and drug discovery and development. |
 Quattromed
is a biotechnology company offering products and services to researchers
in functional genomics and proteomics area. Quattromed has developed
systems for protein expression analyses in mammalian, bacterial, yeast
and plant cells that use new E2Tag epitope tag. We provide cloning,
expression, stable cell line development, recombinant adeno- and baculovirus
and SF virus construction services. |
Scanalytics
Scanalytics gives "sight" to computers, by creating software that
captures images from digital cameras and extracts information from
those images. We integrate our software into high-performance vision
systems specifically to support scientific researchers in biotechnology
and life sciences. |
 Scimagix
ProteinMin™ is designed to extract, analyze and mine protein
image-data from 2D electrophoresis gels. It extracts an index of the
visual characteristics of a 2D gel experiment and places it into a
database. The proteomics scientists can then query their entire collection
of gel experiments to find similar "protein signatures." The first
of a series of plug-in modules for SIMS, ProteinMine features: Automatic
spot detection; Unwarping; Easy user interface for manual adjustments;
Automatic registration of all spots into Oracle; Ability to search
all experiments for "protein signatures" |
 Sense
Proteomic Limited is a functional proteomics company that aims to
be a World leader in the development and use of protein-related molecular
technologies to enhance the productivity of the drug discovery process
and the efficacy of the therapies developed from it. These aims shall
be achieved through technology developments in collaboration with
pharmaceutical and biotechnology companies; the development, production
and marketing of functional protein arrays; and the discovery of novel
drug targets and leads through the application of its technologies.
Sense Proteomic was spun out from BritainÕs two oldest universities:
Oxford and Cambridge, being founded by Dr Roland Kozlowski and Dr
Jonathan Blackburn. The Company received its first round funding of
£3m in Autumn 2000 from Apax Partners & Co and is planning to raise
further capital in 2002 to further develop its technologies and products.
|
 Signature
BioScience is a development stage biotech company which is creating
a breakthrough technology platform for true functional proteomics.
Our system enables real-time, label-free observation of the activities
of proteins under their natural, unperturbed conditions. By embedding
our technology as a new component of the drug screening process, we
believe the pace and quality of discovery of both new drug targets
and new medicines will be significantly increased. Signature's drug
discovery strategy is to evaluate potential new targets and compounds
in parallel, and screen for specific physiologic activity at the earliest
points in the discovery process. This strategy has resulted in WaveScreen,
Signature's unique discovery platform that combines complementary
screening technologies with assays and chemistries to facilitate access
to a wide range of biological activities. Signature's proprietary
technologies include a microwave-based spectroscopy, known as MCS,
and Cytection, a high-throughput bioassay using primary human cells.
|
 The
sequencing of the human genome sets the stage for proteomics - the
large-scale analysis of proteins. By revealing the complex relationships
between proteins and both disease and health, proteomics will create
unprecedented opportunities in the research and clinical arenas. SomaLogic's
arrays for proteomics will be based on the company's proprietary photoaptamer
technology and will allow the simultaneous quantitative analysis of
multiple proteins. Initial applications will be offered to life sciences
and clinical researchers on a service basis and will focus on inflammation
and angiogenesis. Through time, SomaLogic will expand its arrays to
other protein families of interest and offer stand-alone proteomic
analysis systems. SomaLogic's clinical development efforts will use
these same arrays as the basis for a new generation of diagnostics.
Through the discovery of the complex patterns of protein expression
associated with health and disease, SomaLogic will help drive a new
approach to clinical medicine. |
 Structural
Bioinformatics, Inc. (SBI) is a world leader in proteomics-driven
drug discovery the large-scale generation and use of protein structural
information to accelerate the discovery and optimization processes.
SBIÕs Genes to Leads¨ technology, employing SBIÕs proprietary DynaPharm®
and CombiLib® technologies, offers a truly practical response
to the wealth of new drug targets emerging from genomic sequencing
efforts around the world for the human genome and the genomes of hundreds
of infectious disease agents. Our technology reliably produces drug
leads in 60-120 days starting with the sequence alone, with an efficiency
that is more than 1,000-fold greater than state-of-the-art high throughput
screening (HTS). The efficiencies in speed and cost are the direct
result of the use of our underlying proprietary computational proteomics
platform that allows us to generate X-ray quality protein structures
at a fraction of the cost and time. We further leverage our proteomics,
pattern recognition, and data fusion technologies through our structural
database products: the ProMax™ drug target database - containing
thousands of proprietary drug target and Òanti-targetÓ structures
in more than 470 structural families; the Variomeª family of structural
polymorphism databases containing tens of thousands of unique polymorphism
structures - providing pharmacogenomics insights early on in the drug
discovery process; and StructureBank™ a universal repository
and enterprise-wide solution for large-scale storage and comparative
analysis of protein structures. |
 Structural
GenomiX (SGX) is revolutionizing the use of protein structure in the
drug discovery process, helping to create safer, more effective medicines.
Using high-throughput structural biology, SGX is translating the wealth
of genetic and genomic information generated over recent years into
structural templates for drug discovery, on an industrial scale. Availability
of the 3-dimensional structure of a protein target can aid drug discovery
at many points in the process, particularly in lead discovery and
optimization, as well as at the earlier stages of target identification
and validation. |
 The
Spendlove Research Foundation was founded in 1989 and is funded through
an endowment established by Dr. Rex S. and Reta Spendlove. Dr. Spendlove
is the Founder of Hyclone Laboratories, a leading producer and distributor
of cell culture media products throughout the world. From its inception
up until 1997 the Spendlove Research Foundation supported outside
researchers through capital investments and other forms of financial
support. In March of 1997 the Spendlove Research Foundation changed
its strategy to concentrating on and supporting its own research projects.
This has allowed the Spendlove Research Foundation to control both
the direction and the emphasis of various research and development
projects. The Spendlove Research Foundation is located in beautiful
Cache Valley in Northern Utah near Utah State University in Logan.
The close proximity to the University allows the Foundation to hire
highly trained and qualified individuals who desire to continue their
education in the pursuit of advanced degrees. Our long-term research
goals focus in the area of in vivo cell culture simulation. This research
centers on specialty cell culture media that will eventually allow
researchers to control the activities of the cell through the media
and cell environment. In order to achieve that end, we are developing
special analytical systems to allow us to measure the biochemical
components in blood, organs, and cells. We are in the business of
technology development and transfer. We develop unique and beneficial
technologies in-house and out-license them for commercialization.
In order to increase the probability of commercialization success,
we will generally give narrow rather than broad licenses - licensing
the technology to many companies, to sell to many markets. |
 SurroMed's
platform for biological marker discovery incorporates proprietary
technologies for profiling and analyzing thousands of immune cell
populations, proteins and low-molecular-weight organic molecules in
small volumes of blood and/or other biological samples. By capturing,
integrating and analyzing large amounts of clinical and biological
informationÑat the level of the cell, gene, protein, and low-molecular-weight
organic moleculeÑSurroMed is able to identify useful biological markers
and provide a detailed picture, or "fingerprint," of pathways involved
in disease and therapeutic response. SurroMed analyzes samples in
its Biomarker Discovery Laboratory under stringent quality control
procedures designed to ensure sample accountability and data integrity.
|
 SYNX
Pharma Inc. is a fully integrated proteomics research and development
company dedicated to prevention and management of diabetes, cardiovascular
and central nervous system diseases. The company leverages its Proteomics
Discovery Platform™ to deliver disease-associated biomarkers
for the development of new drugs and highly specialized antibody-based
diagnostics by analyzing human biological material. SYNX brings value-added
solutions to its partners by helping them expand the market for current
therapies, while significantly shortening the drug discovery and testing
process, resulting in products being brought quickly to market, thereby
extending their functional commercial life. Physicians also benefit
from SYNX's expertise, by being able to diagnose disease in its earliest
stages, follow its progression and suggest the most effective course
of treatment to improve patient outcomes. |
 Syrrx,
Inc. is a drug discovery company committed to redefining the way medicines
is discovered. Based in San Diego, CA, the company is at the forefront
of high-throughput rational drug discovery. Syrrx intends to leverage
high-throughput structure determination, high-throughput screening,
combinatorial and medicinal chemistry together with computational
methods to discover novel small molecule preclinical drug candidates.
This process enables a unique "gene to drug" platform based on the
ability to perform high-throughput rational drug discovery. |
 Thermo
Finnigan, a Thermo Electron business, supports laboratory professionals
with the most reliable products and services available. Thermo Finnigan
makes mass spectrometry and chromatography equipment, among the most
accurate and sensitive available, for analyzing a wide array of substances.
The business is one of the world's leading manufacturers of these
instruments, which separate, identify, and quantify natural products,
chemical mixtures and biological samples. The business serves markets
totaling an estimated $8 billion worldwide. |
Vertex's information-driven drug design approach combines diverse
technology disciplines and an integrated organizational philosophy
to increase the speed and success rate of drug discovery and development.
The information-driven drug design approach is dynamic-it has incorporated
and continues to integrate new technologies within the framework of
core biology, chemistry and biophysics disciplines. Vertex has developed
a variety of advanced and proprietary approaches, including compound
screening using NMR SHAPES, virtual screening using computer modeling
and combinatorial chemistry, and early incorporation of pharmacological
testing to drive the drug discovery process. By using these approaches,
as well as a range of available technologies, including use of x-ray
crystallography to determine the three-dimensional structure of a
drug target, Vertex has been able to accelerate drug discovery timelines
and increase success rates in early development compared to industry
averages. |
 WITA
Proteomics is dedicated to providing complete proteomics solutions
to partners interested in understanding the identity and potential
role of proteins from a specific cellular source under particular
conditions. Our position as a leading partner for ultra high-resolution
proteomics, our High Performance Proteomics™, analysis is demonstrated
by the meaningful results we deliver to our partners. WITA's High
Performance Proteomics™ platform provides unparalleled spot resolution,
up to 10,000 protein spots per gel, a greater then 5 fold advantage
over competing methodologies. In conjunction with Sypro Ruby™
staining we offer the most sensitive protein detection and identification
solution available. WITA differentiates itself from a number of proteomics
companies in that it goes beyond the process of identifying proteins,
their modifications, sequence analysis and database compilation and
licensing. In addition to delivering these data we deliver an analysis
of the biochemical implication of the presence of modified proteins,
and the strategic use of such information for drug development as
well as for diagnostic use. |
Xerion
Pharmaceuticals (founded in 1998) is a functional proteomics company
located in Martinsried/Munich, one of Europe's hottest biotech clusters.
The combination of our powerful vision, corporate culture, smart
and energized people, and innovative technology make us stand out
against others. Xerion provides viable and profitable drug development
solutions. Xerion focuses on proteins, the molecules that perform
most biological functions and represent the vast majority of today's
and tomorrow's drug targets. The Company has assembled and combined
unique and effective technologies for drug target identification
(Xcelerate™), validation (XCALIbur™) and functional site
identification (X-plore™). The core technology of the platform
is XCALIbur™, a proprietary method for specific functional
analysis of proteins which Xerion has established as a target validation
tool. This centerpiece is complemented by combinatorial biology
and mass spectrometry for target and functional site identification.
These technologies optimize critical steps in the drug development
process to provide valuable solutions in the search for novel, safe
and therapeutic drugs. This makes us a technology leader in functional
proteomics.
|
 Zyomyx
has developed technology that enables proteins to be analyzed with
the kind of precision and throughput that automated sequencers and
DNA chips brought to the study of our genes. Not just an adaptation
of DNA chip technology - the Zyomyx platform was designed from the
ground up for proteins. A result of over 250 man-years of focused
research and development, it is the only platform to deliver the needed
combination of biological specificity, high sample throughput, sensitivity,
and massive parallelism. The power of Zyomyx' technology will be utilized
by pharmaceutical and biotech companies to validate the backlog of
targets created by their genomics programs, to study the mechanism
of action for new drug leads, and to enable real time monitoring of
therapeutic response and potential side effects. It will also enable
diagnostics companies to move quickly, identify new biological markers,
and enable clinicians to run hundreds of tests from a single drop
of blood or small tissue samples. Given the flexibility and broad
applicability of the technology there will likely be numerous other
applications throughout life science research and in other fields.
Zyomyx will profit by supplying proteomics research tools and by collaborating
with others to apply them in pharmaceutical research. It will also
supply technology and components to other companies pursuing complementary
applications. |
| |
| |
| |
| |
|
